EAU26 Afternoon Dialogue | Xuesong Li: ADC Plus Radiotherapy in the Perioperative Setting Breaks Therapeutic Barriers and Opens a New Era of Precision Treatment for UTUC

EAU26 Afternoon Dialogue | Xuesong Li: ADC Plus Radiotherapy in the Perioperative Setting Breaks Therapeutic Barriers and Opens a New Era of Precision Treatment for UTUC

At the 2026 European Association of Urology Congress (EAU26), held in London, major advances in urologic oncology were presented. Among them, the work of Professor Xuesong Li’s team from Peking University First Hospital attracted considerable attention. The team not only contributed important achievements in upper urinary tract reconstruction but also presented a phase II clinical study of disitamab vedotin combined with radiotherapy for upper tract urothelial carcinoma (UTUC), offering a promising new treatment option.
EAU 2026 Afternoon Dialogue | Fred Saad: Frontiers in Prostate Cancer Treatment and the Future Landscape

EAU 2026 Afternoon Dialogue | Fred Saad: Frontiers in Prostate Cancer Treatment and the Future Landscape

At the 2026 European Association of Urology (EAU) Annual Congress held in London, leading experts from around the world gathered to discuss the latest advances and evolving clinical practices in genitourinary oncology. During the meeting, Oncology Frontier had the privilege of interviewing Professor Fred Saad from the Centre Hospitalier de l’Université de Montréal, who shared key insights into his team’s latest research, major breakthroughs in prostate cancer, and future therapeutic directions.
EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML

EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
EBMT 2026 China Voice | Professor Xiaojun Huang: Haploidentical Hematopoietic Stem Cell Transplantation for Rare Diseases — Practice and Insights from the Beijing Protocol

EBMT 2026 China Voice | Professor Xiaojun Huang: Haploidentical Hematopoietic Stem Cell Transplantation for Rare Diseases — Practice and Insights from the Beijing Protocol

Over the past 15 years, the field of hematopoietic stem cell transplantation has undergone a profound transformation, largely driven by breakthroughs in haploidentical transplantation. Represented by the “Beijing Protocol” pioneered by Professor Xiaojun Huang and his team at Peking University People’s Hospital, haploidentical transplantation has not only overcome the long-standing limitation of donor availability but has also achieved outstanding outcomes in the treatment of hematologic malignancies, leading to its widespread adoption worldwide.
EBMT 2026 China Voice | Professor Jia Wei: A Powerful Combination Strategy Reshaping the Tumor Microenvironment and Opening a New Era of Durable Benefit in CAR-T Therapy

EBMT 2026 China Voice | Professor Jia Wei: A Powerful Combination Strategy Reshaping the Tumor Microenvironment and Opening a New Era of Durable Benefit in CAR-T Therapy

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. The congress gathered thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy, covering key topics such as optimization of transplant strategies, infection management, CAR-T therapy, and graft-versus-host disease (GVHD) management.
EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better

EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential academic events in the field, the congress brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
EBMT 2026 Highlights | Restoring T-cell Fitness and Enhancing CAR-T Expansion in Bendamustine-Exposed R/R B-NHL

EBMT 2026 Highlights | Restoring T-cell Fitness and Enhancing CAR-T Expansion in Bendamustine-Exposed R/R B-NHL

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential international conferences in hematology, EBMT brings together experts worldwide to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapy.
EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL

EBMT 2026 China Voice | Professor Xing-Yu Cao: Sequential CD7 CAR-T Followed by Second Transplant Improves Survival to Nearly 50% in Post-Transplant Relapsed T-ALL/LBL

Patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have an extremely poor prognosis. Historically, treatment options have been limited, and even with a second transplant, long-term survival has remained below 30%. There is therefore an urgent need for more effective therapeutic strategies.